The challenge of developing new therapies for irritable bowel syndrome

Agrawal, A. and Whorwell, P.J. (2006) Irritable bowel syndrome: diagnosis and management . BMJ 332: 280-283.

Camilleri, M. , Northcutt, A.R. , Kong, S. , Dukes, G.E. , Mcsorley, D. and Mangel, A.W. (2000) Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355: 1035-1040.

Drossman, D. , Morris, C. , Schneck, S. , Hu, Y. , Norton, N. , Norton, W. et al. (2009) International survey of patients with IBS: symptom features and their severity, health status, treatments and risk taking to achieve clinical benefit. J Clinical Gastroenterol [in press].

Drossman, D.A. , Camilleri, M. , Mayer, E.A. and Whitehead, W.E. (2002) AGA technical review on irritable bowel syndrome . Gastroenterology 123: 2108-2131.

Gershon, M. (2002) Importance of serotonergic mechanisms in gastrointestinal motility and secretion. In: Camilleri, M. and Spiller, R. (eds). Irritable Bowel Syndrome: Diagnosis and Management. London : WB Saunders.

Gralnek, I.M. , Hays, R.D. , Kilbourne, A. , Naliboff, B. and Mayer, E.A. (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119: 654-660.

Guthrie, E. , Creed, F.H. and Whorwell, P.J. (1987) Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration . Br Med J (Clin Res Ed) 295: 577-578.

Houghton, L.A. and Whorwell, P.J. (2005) Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 17: 500-511.

Longstreth, G.F. (1995) Irritable bowel syndrome: a multibillion-dollar problem. Gastroenterology 109: 2029-2031.

Miller, V. , Hopkins, L. and Whorwell, P.J. (2004) Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2: 1064-1068.

Muller-Lissner, S.A. , Fumagalli, I. , Bardhan, K.D. , Pace, F. , Pecher, E. , Nault, B. et al. (2001) Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15: 1655-1666.

Whorwell, P.J. , McCallum, M. , Creed, F.H. and Roberts, C.T. (1986) Non-colonic features of irritable bowel syndrome . Gut 27: 37-40.